Clinical Trials Logo

AL Amyloidosis clinical trials

View clinical trials related to AL Amyloidosis.

Filter by:

NCT ID: NCT05199337 Active, not recruiting - Amyloidosis Clinical Trials

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Start date: November 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.

NCT ID: NCT05184088 Recruiting - AL Amyloidosis Clinical Trials

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

CArdiag
Start date: January 13, 2023
Phase: Phase 3
Study type: Interventional

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

NCT ID: NCT05145816 Recruiting - Amyloidosis Clinical Trials

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Start date: February 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety, tolerability, recommended phase II (RP2) dose, and efficacy of Belantamab mafodotin for participants with Relapsed Refractory AL Amyloidosis (RRAL.)

NCT ID: NCT05066607 Recruiting - AL Amyloidosis Clinical Trials

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

IsAMYP
Start date: February 11, 2022
Phase: Phase 2
Study type: Interventional

This phase 2 study ain to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy. It will enrolled 46 patients (34 in France and 12 in Australia) through 15 sites (11 in France and 4 in Australia).

NCT ID: NCT05028374 Completed - Multiple Myeloma Clinical Trials

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Start date: August 17, 2021
Phase: Phase 2
Study type: Interventional

To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were authorized for use in the USA. Researchers will also assess whether the booster dosing with the Moderna COVID-19 vaccine is safe in patients with multiple myeloma, amyloidosis, or other blood cancers.

NCT ID: NCT04984330 Withdrawn - Amyloidosis Clinical Trials

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

STARR
Start date: December 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.

NCT ID: NCT04937777 Completed - AL Amyloidosis Clinical Trials

A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe

Start date: April 23, 2019
Phase:
Study type: Observational

This is a retrospective, observational, multicenter study to collect Real-World Evidence (RWE) data on systemic AL-AMY patients in Europe. Data from paper/electronic medical records and/or electronic databases from key reference centers in Europe will be used. Data will either be entered by the site staff in the electronic Case Report Form (eCRF) or, where feasible, transferred directly, always in accordance to local regulations.

NCT ID: NCT04895917 Recruiting - AL Amyloidosis Clinical Trials

Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis

DarPAL
Start date: June 23, 2021
Phase: Phase 2
Study type: Interventional

This study aims at establishing a new powerful combination of daratumumab and pomalidomide as rescue treatment for patients with R/R AL amyloidosis.

NCT ID: NCT04847453 Recruiting - AL Amyloidosis Clinical Trials

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Start date: August 3, 2022
Phase: Phase 1
Study type: Interventional

This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abnormal genetic change [translocation t(11;14)]. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ixazomib citrate is in a class of medications called proteasome inhibitors. It works by helping to kill cancer cells. Anti-inflammatory drugs such as dexamethasone reduce inflammation by lowering the body's immune response and are used with other drugs in the treatment of some types of cancer. Combination therapy with venetoclax, ixazomib citrate and dexamethasone may be effective in treatment of relapsed or refractory light chain amyloidosis.

NCT ID: NCT04839003 Recruiting - AL Amyloidosis Clinical Trials

A Registry of AL Amyloidosis (ReAL)

ReAL
Start date: February 27, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.